In order to clarify whether SENP2 regulated stemness and sensitivity to sorafenib through AKT/GSK3β/CTNNB1 signaling in HCC cell lines, compensation experiments were conducted. The gene discussed is GSK3B; the disease is hepatocellular carcinoma.